Comparative Pharmacology
Head-to-head clinical analysis: ENULOSE versus HEPTALAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENULOSE versus HEPTALAC.
ENULOSE vs HEPTALAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic pH and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
Ammonia scavenger; lactulose is metabolized by colonic bacteria to organic acids, acidifying the colon, which converts NH3 to NH4+ and promotes ammonia excretion. Lactulose also reduces colonic transit time and bacterial production of ammonia.
15-45 mL orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 mL per day.
Oral: 3.33 g (30 mL) 3 times daily. Rectal: 200 mL of 30% solution as retention enema, 3 times daily. Intravenous: 30 g as a single dose via intra-abdominal instillation.
None Documented
None Documented
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Terminal elimination half-life is 6-12 hours in patients with normal hepatic function; prolonged in hepatic encephalopathy due to altered clearance (up to 24 hours).
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Primarily renal (approximately 70-80%) as unchanged drug; minor biliary/fecal elimination (20-30%).
Category C
Category C
Laxative
Laxative